NAMS - NEWAMSTERDAM PHARMA COMPANY
This page shows which of the focused investors we track hold NAMS and how their positions changed, so you can see how much conviction the group has in the stock.
In Q4 2024 it was held by 3 managers with an aggregate reported value of $195.73M, which is 0.02% of the combined portfolio.
As of Q4 2024, 3 tracked institutional managers held NAMS (NEWAMSTERDAM PHARMA COMPANY) with an aggregate reported value of $195.73M — 0.02% of the combined AlphaBaseline portfolio.
Get email alerts when a tracked manager trades NAMS — sign in or create a free account.
- Source
- Curated SEC 13F filings
- Period
- Q4 2024
- Ticker
- NAMS
13F data is delayed and excludes shorts/non-13F assets.
Holders
| 1 | Viking Global Investors - Viking Global Investors | 0.58% | Reduce -13.0% | 6,978,534 | $179.35M |
| 2 | Lee Ainslie - Maverick Capital | 0.16% | New | 350,005 | $9M |
| 3 | Stanley Druckenmiller - Duquesne Family Office LLC | 0.21% | - | 287,535 | $7.39M |
Loading holder history for NAMS…